Orchestra BioMed Holdings, Inc. Ordinary Shares OBIO
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $13.00 (+140.3% upside)
Key Stats
- Today's Range
- $5.31 – $5.41
- 50-Day Range
- $3.56 – $5.78
- 52-Week Range
- $2.20 – $5.78
- Volume
- 5K shs
- Average Volume
- 290K shs
- Market Cap
- $326.37 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.05%
- Days to Cover
- 1.00
About Orchestra BioMed Holdings, Inc. Ordinary Shares
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Related Stocks
Compare head-to-head: OBIO vs SYK·OBIO vs BSX·OBIO vs RMD·OBIO vs BAX
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.